Compare FFIN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | CRNX |
|---|---|---|
| Founded | 1890 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | FFIN | CRNX |
|---|---|---|
| Price | $29.95 | $36.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $37.50 | ★ $76.63 |
| AVG Volume (30 Days) | 677.6K | ★ 1.1M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 13.46 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $17.16 | $720.10 |
| Revenue Next Year | $6.61 | $184.67 |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.12 | $24.10 |
| 52 Week High | $38.74 | $57.99 |
| Indicator | FFIN | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 46.73 |
| Support Level | $29.44 | $33.23 |
| Resistance Level | $30.21 | $45.32 |
| Average True Range (ATR) | 0.66 | 1.68 |
| MACD | 0.18 | 0.50 |
| Stochastic Oscillator | 89.02 | 76.62 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.